Erlotinib a first-generation EGFR TKI is currently approved for patients with non-small cell lung cancer and first line of treatment for metastatic or locally advanced pancreatic cancer in combination with gemcitabine [8]. This evidence concerns the gene EGFR and pancreatic neoplasm.